Clinical Trials Logo

Clinical Trial Summary

A chart review study of patients with haemophilia A with inhibitors treated with rFVIIIFc (Elocta®) for immune tolerance induction.


Clinical Trial Description

A multicenter, international, non- interventional, retrospective and prospective medical chart review study. Data will be collected from medical records for patients diagnosed with haemophilia A who have been, or who are currently, treated with rFVIIIFc for ITI . The study will be descriptive in nature and report on baseline characteristics, treatment and outcomes for patients who have been, or who are currently, treated with rFVIIIFc for ITI. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03951103
Study type Observational
Source Swedish Orphan Biovitrum
Contact
Status Completed
Phase
Start date November 7, 2018
Completion date September 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06320626 - Pharmacokinetic-guided Dosing of Emicizumab Phase 4
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Not yet recruiting NCT02554526 - Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors N/A
Completed NCT03818529 - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Active, not recruiting NCT03619863 - ATHN 7: Hemophilia Natural History Study
Recruiting NCT06010953 - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment Phase 1/Phase 2
Recruiting NCT05888870 - ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor Phase 4
Terminated NCT04303572 - The Hemophilia Inhibitor Eradication Trial Phase 3
Terminated NCT04489537 - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B Phase 3
Terminated NCT04548791 - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Phase 1/Phase 2
Completed NCT06357572 - Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem
Recruiting NCT04647227 - SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors Phase 4
Completed NCT03372993 - Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
Terminated NCT03204539 - INdividualized ITI Based on Fviii(ATE) Protection by VWF Phase 4
Active, not recruiting NCT04205175 - A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab Phase 4
Recruiting NCT06312475 - Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors Phase 3
Recruiting NCT03598725 - Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China Phase 4
Completed NCT04723693 - An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
Completed NCT04789954 - Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors Early Phase 1
Recruiting NCT04592692 - A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip Phase 2